Tumor Biology

, Volume 36, Issue 10, pp 7659–7665 | Cite as

Clinical significance of high expression of circulating serum lncRNA RP11-445H22.4 in breast cancer patients: a Chinese population-based study

  • Nan Xu
  • Fei Chen
  • Fengliang Wang
  • Xun Lu
  • Xu Wang
  • Mingming Lv
  • Cheng Lu
Research Article


Long noncoding RNAs (lncRNAs) have been gradually confirmed to be tumor-associated biological molecules and became interesting new diagnostic targets of cancer. However, the clinical significances of most cancer-related lncRNAs are largely unknown. Here, we evaluated, for the first time, the feasibility and clinical significances of circulating serum lncRNA RP11-445H22.4 as biomarker for the detection of breast cancer (BC). In this study, the relative concentrations of breast cancer-associated lncRNA RP11-445H22.4 were investigated in a total of 136 serum samples by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). The correlations between the levels of serum lncRNA RP11-445H22.4 in breast cancer patients and the clinicopathological factors of these patients were further analyzed. Receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic values. In breast cancer patients, the expression level of lncRNA RP11-445H22.4 is significantly increased (p < 0.001). The sensitivity and specificity of RP11-445H22.4 for BC were 92 and 74 %, respectively. Its expression levels were correlated with estrogen receptor (ER), progesterone receptor (PR), and menopausal status of the breast cancer patients (p < 0.05). For the detection of breast cancer, the use of RP11-445H22.4 showed a remarkable improvement compared with the clinical serum carcinoembryonic antigen. In conclusions, lncRNA RP11-445H22.4 may be a new potential biomarker of breast cancer.


Breast cancer lncRNA RP11-445H22.4 Serum biomarker 



This work was supported by a grant from the National Science Foundation of China (No. 81172501) and Nanjing Medical Science and Technology Development Foundation (No. YKK12103).

Conflicts of interest



  1. 1.
    De Santis C, Ma J, Bryan L, et al. Breast cancer statistics. CA Cancer J Clin. 2014;64(1):52–62.CrossRefGoogle Scholar
  2. 2.
    Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRefGoogle Scholar
  3. 3.
    Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19(8):1893–907.CrossRefGoogle Scholar
  4. 4.
    Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Marić P, Ozretić P, Levanat S, et al. Tumor markers in breast cancer—evaluation of their clinical usefulness. Coll Antropol. 2011;35(1):241–7.PubMedGoogle Scholar
  6. 6.
    Wu S, He Z, Zhou J, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23(1):88–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer—European Group on Tumor Markers recommendations. Tumor Biol. 2005;26(6):281–93.CrossRefGoogle Scholar
  8. 8.
    Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.CrossRefPubMedGoogle Scholar
  9. 9.
    Qiu MT, Hu JW, Yin R, et al. Long noncoding RNA: an emerging paradigm of cancer research. Tumor Biol. 2013;34(2):613–20.CrossRefGoogle Scholar
  10. 10.
    Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31(43):4577–87.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Li H, Yu B, Li J, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5(8):2318–29.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409–19.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10(1):38–55.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tong YK, Lo YM. Diagnostic developments involving cell-free (circulating) nucleic acids. Clin Chim Acta. 2006;363(1):187–96.CrossRefPubMedGoogle Scholar
  15. 15.
    Chevli KK, Duff M, Walter P, et al. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol. 2014;191(6):1743–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang FL, Chen F. Effects of age, breast density and volume on breast cancer diagnosis: a retrospective comparison of sensitivity of mammography and ultrasonography in China’s rural areas. Asian Pac J Cancer Prev. 2013;14(4):2277–82.CrossRefPubMedGoogle Scholar
  17. 17.
    Mitrović O, Čokić V, Đikić D, et al. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer. Target Oncol, 2013: 1–13.Google Scholar
  18. 18.
    Banerjee S, Smith IE. Management of small HER2-positive breast cancers. Lancet Oncol. 2010;11(12):1193–9.CrossRefPubMedGoogle Scholar
  19. 19.
    DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.CrossRefPubMedGoogle Scholar
  20. 20.
    Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet, 2013.Google Scholar
  21. 21.
    Zhang H, Chen Z, Wang X, et al. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6(1):1–7.CrossRefGoogle Scholar
  22. 22.
    Gutschner T, Hämmerle M, Eißmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Prensner J R, Iyer M K, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet, 2013.Google Scholar
  24. 24.
    Zhang EB, Han L, Yin DD, et al. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med Oncol. 2014;31(5):1–8.Google Scholar
  25. 25.
    Zhao Y, Guo Q, Chen J, et al. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep. 2014;31(1):358–64.PubMedGoogle Scholar
  26. 26.
    Cheetham SW, Gruhl F, Mattick JS, et al. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108(12):2419–25.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63.CrossRefPubMedGoogle Scholar
  28. 28.
    English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther. 2013;17(2):85–99.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Breast SurgeryNanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical UniversityNanjingChina
  2. 2.First Clinical Medicine CollegeNanjing University of Chinese MedicineNanjingChina
  3. 3.Nanjing Jinling High SchoolNanjingChina

Personalised recommendations